BioVie Inc. (BIVI)
NASDAQ (CM) NASDAQ (CM) Primary 
BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson's disease, with CEO Cuong Do highlighting the company's focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while Parkinson's is commonly associated with dopamine deficiency and loss of muscle control, this represents only part of the disease mechanism.
BioVie targets Parkinson's at its source with lead drug bezisterim
For decades, treatment of Parkinson's disease has centered on replacing dopamine, the neurotransmitter whose decline drives the disease's hallmark motor symptoms. But while therapies such as levodopa can temporarily restore movement, they do little to address the underlying neurodegeneration, and often introduce complications of their own.
Nasdaq, S&P 500 in the red as investors digest slower GDP and steady inflation
4:05pm: In the red US stocks remained under pressure on Friday afternoon as investors reacted to new data indicating slowing economic growth amid the...
BioVie to present Parkinson's study data at AD/PD 2026 conference
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 Advances in Science & Therapy annual meeting. The conference is scheduled to take place March 17 to 21, 2026, in Copenhagen, Denmark.
BioVie highlights bezisterim research at ACP meeting
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate bezisterim (NE3107) have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida. The abstracts, which focus on bezisterim's potential in Alzheimer's disease and Long COVID, will be presented as posters on February 18.
BioVie could offer first new Parkinson's therapy in decades
In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW), a clinical-stage biopharmaceutical company with a market capitalization still measured in the tens of millions, is attempting exactly that by targeting what it believes is a root driver of neurodegeneration rather than merely treating symptoms.
BioVie hits enrolment milestone in early Parkinson's trial, data due later this year
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson's disease, putting the group on track for key data later this year. The Phase 2 study, known as SUNRISE-PD, has enrolled 60 patients who were diagnosed within the past four years and have not yet been treated with standard levodopa therapy.
BioVie advances lead drug candidates - ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do talked with Proactive about the company's recent developments in its two lead drug candidates: Bezisterim and BIV201. Bezisterim, which blocks TNF alpha to reduce inflammation, is being trialed in Parkinson's disease, long COVID, and Alzheimer's.
What Makes BioVie (BIVI) a New Buy Stock
BioVie (BIVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
BioVie Inc. - Special Call
BioVie Inc. - Special Call Company Participants Cuong Viet Do - President, CEO & Director Conference Call Participants Craig Brelsford Presentation Craig Brelsford Hello. This is Craig Brelsford with RedChip Companies.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
